Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on June 9, 2015. The filing details a strategic shift in the commercialization of the company's PharmacoSurgery product candidate, OMS103, which is designed for use during arthroscopic procedures such as partial meniscectomy surgery.
Key Financial Metrics and Agreements
- Licensing Revenue Potential: Omeros entered an exclusive, royalty-free license agreement with Fagron Compounding Services, LLC and JCB Laboratories, LLC (collectively Fagron). Omeros will receive a substantial majority share of gross revenue from future U.S. sales, guaranteed not to be less than a minimum per unit amount.
- Milestone Payments: Omeros is eligible to receive up to an aggregate total of $10 million in potential payments upon achieving specific commercial milestones and through revenue-share enhancements on early sales.
- Cost Structure: Omeros will incur no further development costs for OMS103, other than maintaining the licensed intellectual property. Fagron is obligated to bear all sales and marketing costs.
- Performance Requirements: Fagron must commence commercial supply in 2015 and meet annual sales volume minimums.
Material Changes Versus Prior Period
- Termination of Prior Agreement: On June 9, 2015, Omeros terminated its Commercial Supply Agreement with Hospira Worldwide Inc., which was effective since October 9, 2007. This termination was in anticipation of discontinuing Omeros' own development of OMS103 and entering the new agreement with Fagron.
- Strategic Pivot: The company shifted from a model where it would purchase commercial supply from Hospira to a model where Fagron handles large-scale production and commercialization in exchange for a revenue share.
Outlook, Risks, and Contingencies
- Outlook: The agreement contemplates potential partnerships for additional products from Omeros' PharmacoSurgery platform. The term continues until the expiration of the last-to-expire patents in the licensed intellectual property.
- Termination Risks: Omeros may terminate the agreement if Fagron fails to meet performance diligence requirements, faces negative regulatory action, or challenges the licensed patents. Either party may terminate for material breach or insolvency.
- Regulatory Contingency: The commercialization is subject to regulatory approval and the ability of Fagron to meet FDA-registered outsourcing facility requirements.
Investor Verification Checklist
- Verify the specific "minimum per unit amount" for the revenue share, as the filing states the share will not be less than this amount but does not disclose the exact figure.
- Confirm the specific commercial milestones required to unlock the up to $10 million in potential payments.
- Monitor Fagron's ability to commence commercial supply of OMS103 within 2015 as required by the diligence obligations.
- Review the attached press release (Exhibit 99.1) for additional details on the partnership structure.